Three commercial pillars, legal overhang, and new safety signals
- INGREZZA remains the core driver, with management raising 2026 guidance to over $2.9 billion.
- CRENESITY is a proven second engine that exceeded $200 million in Q3 2026 sales.
- The VYKAT XR acquisition is paying off, adding $107 million in Q3 revenue.
- The FDA is evaluating a fluid retention safety signal for VYKAT XR.
- A DOJ investigation into INGREZZA sales practices remains a major unquantified risk.
Growth is real, risks are unresolved
Neurocrine successfully transitioned from a single-drug company into a diversified commercial biotech. The $2.9 billion acquisition of Soleno Therapeutics in May 2026 added VYKAT XR, creating a third revenue pillar alongside INGREZZA and CRENESITY.
The bull case relies on sustained commercial momentum. INGREZZA continues to beat expectations, prompting a guidance raise to over $2.9 billion for 2026. CRENESITY has reached over 15 percent of diagnosed CAH patients, and VYKAT XR adds another long-term growth engine before the pipeline matures in 2027.
The bear case centers on coming headwinds and legal risks. Management expects mid-to-high single-digit pricing pressure for INGREZZA in 2027, requiring volume to drive all revenue growth. At the same time, a Department of Justice investigation into INGREZZA sales practices remains an unquantified overhang. Furthermore, the FDA is evaluating a fluid retention safety signal for VYKAT XR, which could negatively impact demand.
Specialty drugs, heavy sales effort
Neurocrine makes money by selling specialized branded medicines. INGREZZA treats tardive dyskinesia, CRENESITY treats congenital adrenal hyperplasia, and VYKAT XR treats hyperphagia in Prader-Willi syndrome.
The company operates a heavy commercial model. It spends significant capital on sales teams, patient support, and market access. This drives top-line growth but raises fixed costs.
The primary vulnerability is operating leverage. If INGREZZA volume slows to meet the 2027 pricing headwinds, or if VYKAT XR faces real-world safety scrutiny, the high sales expenses will compress earnings. Management is betting that aggressive market development will outpace these costs.
Products that carry the story
INGREZZA
The flagship product for tardive dyskinesia and Huntington's disease chorea, expected to clear $2.9 billion in 2026 sales.
CRENESITY
A treatment for congenital adrenal hyperplasia that reached $211 million in Q3 2026 sales.
VYKAT XR
Acquired via the Soleno deal in May 2026, this is the only approved treatment for hyperphagia in Prader-Willi syndrome.
Osuvampator
A late-stage asset in Phase III testing for major depressive disorder, with data expected in 2027.
Direclidine
A Phase III asset for schizophrenia, also expecting top-line results in 2027.
Q3 sales reflect a three-product company
The mix reflects Q3 2026 net product sales, with INGREZZA at $801 million, CRENESITY at $211 million, and VYKAT XR at $107 million.
What could break the thesis
DOJ investigation
High impact · Medium oddsIn 2025, Neurocrine received a Civil Investigative Demand from the Department of Justice regarding INGREZZA sales and marketing. The outcome is unknown and could result in fines or limits on sales practices.
VYKAT XR fluid retention safety signal
Medium impact · Medium oddsThe FDA is evaluating a potential safety signal regarding fluid retention in patients taking VYKAT XR. Patient advocacy groups have also issued related warnings. This scrutiny could stall adoption or lead to label restrictions.
2027 INGREZZA pricing pressure
Medium impact · High oddsManagement expects mid-to-high single-digit net pricing headwinds for INGREZZA in 2027. The company must maintain double-digit volume growth just to offset these price declines.
2027 pipeline misses
Medium impact · Medium oddsOsuvampator and direclidine represent the next growth wave. Both face critical Phase III readouts in 2027. Trial failures would cut future optionality.
In one breath
What does Neurocrine Biosciences sell?
Neurocrine sells branded medicines for neurological, endocrine, and psychiatric disorders. Its biggest product is INGREZZA, and its newer growth products are CRENESITY and VYKAT XR.
Why does INGREZZA matter so much to NBIX?
INGREZZA produced $801 million of Q3 2026 sales, making it the main driver of the company. That scale funds sales investments, acquisitions, and pipeline work.
What is the main risk for NBIX stock?
The biggest specific risk is the DOJ investigation into INGREZZA sales and marketing. Additional key risks include a new FDA safety signal evaluation for VYKAT XR and expected 2027 pricing headwinds for INGREZZA.
When could the pipeline matter?
The next major pipeline moments are expected in 2027. Neurocrine expects top-line Phase III results for osuvampator in major depressive disorder and direclidine in schizophrenia.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - Specialty & Generic companies
Companies near Neurocrine Biosciences, Inc. in Finn's Drug Manufacturers - Specialty & Generic industry ranking.

